AKT1 and breast carcinoma: More interestingly, re‐introducing WT, but not the enzyme‐inactive variant Nedd4l‐C962A, could inhibit AKT phosphorylation in NEDD4L‐depleted breast cancer cells, coupled with decreased CTR1 protein levels (Figure 5c).